Specific mutated BRCA regions confer different risks of breast, ovarian cancers
the ONA take:
According to a new study published in JAMA, researchers at the The Basser Center for BRCA, the Perelman School of Medicine at the University of Pennsylvania, and the Abramson Cancer Cancer Center, have found specific BRCA mutations confer higher risks of breast cancer, while other BRCA mutations confer higher risks of ovarian cancer.
For the study, researchers evaluated cancer diagnoses for 19,581 carriers of BRCA1 mutations and 11,900 carriers of BRCA2 mutations. Results showed that women who carry a certain subset of BRCA mutations typically found in the Ashkenazi Jewish population have a 69% risk of breast cancer and a 26% ovarian cancer.
Previous research showed that a woman with a BRCA1 mutations automatically has a 59% risk of breast cancer and a 34% risk of ovarian cancer.
The findings suggest that there are certain regions on the BRCA1 and BRCA2 genes that, when mutated, increase a woman's risk for breast cancer, while other mutated regions increase a woman's risk for ovarian cancer.
Specific BRCA mutations confer higher risks of breast cancer, while other BRCA mutations confer higher risks of ovarian cancer.
- Sexual Dysfunction in Women With Cancer: A Review of Available Interventions
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Affect of Daratumumab on Laboratory Blood Test Results
- Geriatric Consults Rare in Kidney Cancer Care
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|